-+ 0.00%
-+ 0.00%
-+ 0.00%

AbbVie says EU approves Rinvoq for children with polyarticular juvenile idiopathic arthritis

PUBT·09/22/2026 06:01:15
Listen to the news
AbbVie says EU approves Rinvoq for children with polyarticular juvenile idiopathic arthritis
  • European Commission cleared AbbVie’s Rinvoq for active polyarticular juvenile idiopathic arthritis in patients aged 2 and older.
  • Use targets children who failed or cannot tolerate at least one DMARD; dosing includes 15 mg tablets or weight-based oral solution.
  • Decision relied on the open-label Phase 1 SELECT-YOUTH pediatric study, supported by adult rheumatoid arthritis data.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609220200PR_NEWS_USPR_____CG39904) on September 22, 2026, and is solely responsible for the information contained therein.